Entropy Neurodynamics

Entropy Neurodynamics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is -15.40. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -6.97 — a change of 120.99% (lower).

EV/FCF

-15.40

YoY

120.99%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Entropy Neurodynamics is 2026 -15.40 . EV/FCF (Enterprise Value to Free Cash Flow) of Entropy Neurodynamics was 2025 -6.97 . It decreases by 120.99% lower compared to the previous year.

The Entropy Neurodynamics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-19.75 AUD
Jan 1, 2020
-7.79 AUD
Jan 1, 2021
-4.91 AUD
Jan 1, 2022
-5.87 AUD
Jan 1, 2023
-14.41 AUD
Jan 1, 2024
-8.79 AUD
Jan 1, 2025
-6.97 AUD
Jan 1, 2026
-15.40 AUD
The Entropy Neurodynamics EV/FCF history
YEAREV/FCFYoY
-15.40+120.99%
-6.97-20.71%
-8.79-38.99%
-14.41+145.61%
-5.87+19.37%
-4.91-36.94%
-7.79-60.55%
-19.75-96.09%
-505.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Entropy Neurodynamics is -15.40 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Entropy Neurodynamics changed from -6.97 to -15.40, representing a 120.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics